title: [TREATMENT OF PATIENTS WITH CHRONIC RECURRENT HERPES VIRUS INFECTION OF GENITAL LOCALIZATION: A CLINICAL STUDY OF FORTEPREN PREPARATION].
abstract: OBJECTIVE
  Selection of optimal dosage regimen, length of treatment course (frequency of administration), safety, tolerance and clinical effectiveness evaluation of the medical preparation fortepren in patients with chronical recurrent herpes virus infection of genital localization.
  
  
  METHODS
  The medical product of antiviral and immune modulating effect--fortepren (sodium polyprenyl phosphate) as a 4 mg/ml solution for injections combined with the base course of acyclic nucleoside acyclovir, 400 mg tablets, held studies. 40 male and female patients participated in the study. After a 10-day acyclovir course (400 mg x 3 times a day) for removing the acute phase, 4 groups of 10 individuals were formed: 1--5 ml (20 mg) of fortepren i/m once at day 13 ± 2 after the start of the study after the completion of the treatment of the acute phase of the disease; 2--5 ml (20 mg) fortepren i/m 3 times at an interval of 21 days; 3--2 ml (8 mg) fortepren i/m 3 times at an interval of 21 days; 4 (control)--5 ml of placebo i/m at remission stage 3 times at an interval of 21 days. Increase of the duration of inter-recurrence period, decrease of the severity of the recurrences, state of skin and mucous damage elements, improvements of immunologic parameters were considered during effectiveness evaluation.
  
  
  RESULTS
  Significant differences in the frequency of recurrences of genital herpes were shown for 3 months of observation in experimental and control groups. A significant reduction of genital herpes recurrence frequency from 3.52 ± 0.09 (before treatment) to 2.89 ± 0.08 (after treatment) was noted in patients of group 3 (p < 0.001). The frequency of recurrences in the control group was 3.84 ± 0.10, that was higher than the parameters in all the experimental groups. A significant reduction of the rash area was noted in group 3, moreover, a redution of frequency of detection of clinical manifestations of genital herpes in the form of vesicle elements after treatment in groups 2 (p = 0.02) and 3 (p = 0.005) was found. Evaluation of local symptoms has established that burning have caused minimal discomfort for patients of groups 3 and 4 and itch and soreness--of groups 1 and 3. The least pronounced exacerbations were noted in patients of group 3. Intramuscular administration of fortepren preparation was established to result in the increase of titers of leukocyte virus-induced interferon for the whole duration of treatment.
  
  
  CONCLUSIONS
  An intramuscular dose of 2 ml (8 mg) at recurrence stage 3 times at an interval of 21 days after the completion of the 10-day base course of treatment of the acute phase of chronical recurrent herpes virus infection of genital localization using acyclovir was accepted as an optimal dosage regimen. Analysis of the obtained results has shown an acceptable safety profile and a good level of tolerance for fortepren preparation.
authors.forename: A N
authors.initials: AN
authors.lastname: Narovlyansky
authors.forename: A M
authors.initials: AM
authors.lastname: Sedov
authors.forename: A V
authors.initials: AV
authors.lastname: Pronin
authors.forename: A E
authors.initials: AE
authors.lastname: Shulzhenko
authors.forename: A V
authors.initials: AV
authors.lastname: Sanin
authors.forename: I N
authors.initials: IN
authors.lastname: Zuikova
authors.forename: R V
authors.initials: RV
authors.lastname: Schubelko
authors.forename: A Yu
authors.initials: AY
authors.lastname: Savchenko
authors.forename: T M
authors.initials: TM
authors.lastname: Parfenova
authors.forename: A V
authors.initials: AV
authors.lastname: Izmestieva
authors.forename: An V
authors.initials: AV
authors.lastname: Izmestieva
authors.forename: E A
authors.initials: EA
authors.lastname: Grigorieva
authors.forename: O V
authors.initials: OV
authors.lastname: Suprun
authors.forename: I K
authors.initials: IK
authors.lastname: Zubashev
authors.forename: V S
authors.initials: VS
authors.lastname: Kozlov
mesh_terms: D000212:Acyclovir / Q000008:administration & dosage*; D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage*; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D005260:Female; D006558:Herpes Genitalis / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007155:Immunologic Factors; D008297:Male; D008875:Middle Aged; D011106:Polyisoprenyl Phosphates / Q000008:administration & dosage*
chemical_list: D000998:Antiviral Agents; D007155:Immunologic Factors; D011106:Polyisoprenyl Phosphates; C011082:polyprenyl monophosphate; D000212:Acyclovir